Pivotal phase III trial of ODT tramadol [Zertane] for the treatment of premature ejaculation (second US trial).

Trial Profile

Pivotal phase III trial of ODT tramadol [Zertane] for the treatment of premature ejaculation (second US trial).

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Mar 2013

At a glance

  • Drugs Tramadol (Primary)
  • Indications Premature ejaculation
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 11 Mar 2013 The FDA has accepted Ampio Pharmaceuticals' Patient Outcome for Premature Ejaculation (POPE) Questionnaire, which allows filing of an IND in the US for a pivotal trial with POPE as a co-primary endpoint, according to a company media release.
    • 14 Nov 2012 Sites to conduct pivotal trials in the US have been identified, according to an Ampio Pharmaceuticals media release.
    • 25 Jun 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top